相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ATTAX2: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer—Final results of a multicentre phase II trial by the AGITG
N. C. Tebbutt et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors.
C. P. Carden et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
M. Moehler et al.
ANNALS OF ONCOLOGY (2011)
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
J. A. Chan et al.
ANNALS OF ONCOLOGY (2011)
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Chul Kim et al.
INVESTIGATIONAL NEW DRUGS (2011)
Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability
L. Latonen et al.
ONCOGENE (2011)
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
B. F. El-Rayes et al.
ANNALS OF ONCOLOGY (2010)
Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab
Li-Chen Yen et al.
ANNALS OF SURGERY (2010)
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
F. Lordick et al.
BRITISH JOURNAL OF CANCER (2010)
Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients
Sook Ryun Park et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Esophagogastric cancer: Targeted agents
Geoffrey Y. Ku et al.
CANCER TREATMENT REVIEWS (2010)
Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
Isamu Okamoto et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
Alicia F. C. Okines et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer.
M. H. Moehler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Final results of a phase H study of modified FOLFOX6 (inFOLFOX6) and erlotinib (E) in patients with metastatic adenotarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ)
Z. A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neoadjuvant Treatment of Unresectable Medullary Thyroid Cancer With Sunitinib
James M. Cleary et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pyridoxine Is Not Effective to Prevent Hand-Foot Syndrome Associated With Capecitabine Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study
Yoon-Koo Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203
Weijing Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
Toshihiko Doi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
S-W Han et al.
BRITISH JOURNAL OF CANCER (2009)
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
C. Pinto et al.
BRITISH JOURNAL OF CANCER (2009)
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
E. Martinelli et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins
Mar Carmena et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma
Sanjiv S. Agarwala et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Histone Deacetylase Inhibitors in Cancer Therapy
Andrew A. Lane et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin
Daniel D. Karp et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer
Shu Yang et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
Madeleine Hewish et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2009)
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
S. Rao et al.
BRITISH JOURNAL OF CANCER (2008)
Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinornas correlates with potent antiapoptotic functions
Altaf A. Dar et al.
CANCER (2008)
Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo
Daniel Cejka et al.
CANCER BIOLOGY & THERAPY (2008)
The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
Jin Won Kim et al.
CANCER LETTERS (2008)
Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity
Howard Safran et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer
P. C. Enzinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer - Phase II Results from the North Central Cancer Treatment Group (N044B)
Aminah Jatoi et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer
Junichi Matsubara et al.
ONCOLOGY (2008)
Aurora kinase family: A new target for anticancer drug
Teresa Macarulla et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2008)
Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death
Hong-Gang Yu et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients
Eva Lieto et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Standardizing patient-reported outcomes assessment in cancer clinical trials: A patient-reported outcomes measurement information system initiative
Sofia F. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I dose escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
Paul Haluska et al.
CLINICAL CANCER RESEARCH (2007)
Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group
Thomas Beckers et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery
Gennaro Galizia et al.
WORLD JOURNAL OF SURGERY (2007)
A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB
H. L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models
Kaori Fujimoto-Ouchi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor
Masayuki Takeda et al.
CLINICAL CANCER RESEARCH (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cancer genetics of epigenetic genes
Ahmad Miremadi et al.
HUMAN MOLECULAR GENETICS (2007)
Heat shock protein 90: the cancer chaperone
Len Neckers
JOURNAL OF BIOSCIENCES (2007)
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
C. Pinto et al.
ANNALS OF ONCOLOGY (2007)
Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas - Association with poor outcome
Kim L. Wang et al.
CANCER (2007)
Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma
Howard Safran et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo
Sven A. Lang et al.
MOLECULAR CANCER THERAPEUTICS (2007)
HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer
F. Lordick et al.
EJC SUPPLEMENTS (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinorna
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for scirrhous gastric cancer
Kazunori Nakamura et al.
GASTROENTEROLOGY (2006)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
Tomislav Dragovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
Federico Rojo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
HER-2/neu amplification is an independent prognostic factor in gastric cancer
Dong Il Park et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma
Shingo Kanaji et al.
ONCOLOGY (2006)
AKT phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer
E Oki et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Fibroblast growth factor signaling in tumorigenesis
R Grose et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Amplification of HER-2 in gastric carcinoma:: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
M Tanner et al.
ANNALS OF ONCOLOGY (2005)
A comprehensive pathway map of epidermal growth factor receptor signaling
Kanae Oda et al.
MOLECULAR SYSTEMS BIOLOGY (2005)
Polo-like kinases (Plks) and cancer
N Takai et al.
ONCOGENE (2005)
PI3K/Akt/mTOR pathway as a target for cancer therapy
D Morgensztern et al.
ANTI-CANCER DRUGS (2005)
Insulin-like growth factor ligands, receptors, and binding proteins in cancer
E Foulstone et al.
JOURNAL OF PATHOLOGY (2005)
Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue
T Inoue et al.
CANCER SCIENCE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Primary tumor volume of nasopharyngeal carcinoma: Prognostic significance for local control
WM Sze et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol
JP Thomas et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Circulating VEGF levels in the serum of gastric cancer patients - Correlation with pathological variables, patient survival, and tumor surgery
AJ Karayiannakis et al.
ANNALS OF SURGERY (2002)
c-Met expression in gastric cancer with liver metastasis
H Amemiya et al.
ONCOLOGY (2002)
Small molecule modulators of cyclin-dependent kinases for cancer therapy
AM Senderowicz
ONCOGENE (2000)
A novel germ line juxtamembrane Met mutation in human gastric cancer
JH Lee et al.
ONCOGENE (2000)
c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems
H Allgayer et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
